Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01185-7/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ada25&_hsenc=p2ANqtz--DkNXxTxDigBu9BBuc3-HC9wDwD8GkNRoKsP41PBLAoTkbLF8xbT6v1pBdHxz5WW6S4-6NKGdRQReuZ5zkog0_MTJKMA&_hsmi=368028124&utm_content=368028124&utm_source=hs_email